Skip to content

Smoking Cessation Support for Patients With Rheumatologic Diseases Via WhatsApp

The Effect of Supporting Routine Smoking Cessation Interventions With Whatsapp-mediated Motivational Information on Smoking Cessation Success in Active Smokers With Inflammatory Rheumatic Diseases: A Randomized Controlled Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06219551
Enrollment
220
Registered
2024-01-23
Start date
2023-11-10
Completion date
2025-06-30
Last updated
2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Cessation

Keywords

tobacco cessation, rheumatologic diseases, smoking cessation support

Brief summary

Smoking cessation support for patients with rheumatologist diseases is an underestimated issue. In the previous prospective cohort study the investigators determined that with the brief cessation interventions 63.5% of smokers with rheumatologic diseases were willing to quit and the rest 36.4% were not willing. Among the willing group the highest quit rate was detected in the group that admitted to smoking cessation clinic. Therefore to increase the willingness to quit as well as to increase the Access to evidence based tobacco cessation support using new comminication technologies can be relevant. Investigators' aim in this study is to examine the effect of including WhatsApp in the routine smoking cessation practices on the quitting success of active smokers with rheumatic diseases who apply to the Rheumatology outpatient clinic.

Detailed description

In this randomized controlled study, the sample will be randomly divided to 2 arms. In one arm, usual care arm, smoker patients with rheumatologist diseases will be implemented brief smoking cessation interventions and referred to quit lines or smoking cessation services and also directly contacted to get an appointment from the cessation clinic. In the other arm, the intervention arm, smoker patients with rheumatologist diseases will be implemented brief tobacco cessation interventions and directly contacted to get an appointment from cessation clinic and will be send periodically motivational and informative text messages regarding tobacco cessation via WhatsApp. Primary outcome measures will be the quit rate of both arms at 3rd, 6th and 12th month. Secondary outcomes will be access to evidence based smoking cessation support, admission rate of smoking cessation clinic and treatment use duration of cessation medications.

Interventions

OTHERMobile messages via What's App

The information article that was prepared by taking the opinions of academics experienced in adult education, and were prepared as a video by the primary Rheumatologist who performs the randomization and will be shared in the Whatsapp group as information. Additionally, information will be provided once a week regarding the appointment date of the smoking cessation clinic.

Sponsors

Recep Tayyip Erdogan University Training and Research Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Randomized controlled, paralel arm, prospective cohort

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Patients applying to the rheumatology outpatient clinic 2. Those aged 18 and over 3. Those who are active smokers 4. Those diagnosed with inflammatory rheumatic disease 5. Those who gave informed written consent to participate in the study

Exclusion criteria

1. Those with active psychiatric disease diagnoses such as psychosis, major depression, schizophrenia among their current diagnoses 2. Those with cognitive dysfunction

Design outcomes

Primary

MeasureTime frameDescription
Rate of participants with successful quit attempt3-6 and 12 months after the randomizationSuccessful quitter: sustained abstinence since the target quit date will be asked and validated by exhaled breath carbon monoxide measure.

Secondary

MeasureTime frameDescription
Access to evidence based cessation supportWithin one year after the randomizationAdmitters to cessation clinics

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026